المؤلفون: Elina Järvinen, Erkki Soini, Marja-Liisa Sumelahti, Petri Mankinen, Ulla Niskala, Tuomas Lundström, Juhani Ruutiainen

المساهمون: Lääketieteen ja terveysteknologian tiedekunta - Faculty of Medicine and Health Technology, Tampere University, HUS Musculoskeletal and Plastic Surgery, Clinicum, Staff Services, Department of Medicine, University of Helsinki

المصدر: Advances in Therapy

مصطلحات موضوعية: Male, Placebo-controlled study, PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY, PLACEBO-CONTROLLED TRIAL, 0302 clinical medicine, Natalizumab, Neurologia ja psykiatria - Neurology and psychiatry, Cladribine tablets, Medicine, Pharmacology (medical), DISEASE-MODIFYING TREATMENTS, 030212 general & internal medicine, Cladribine, Finland, Original Research, Productivity, UTILITY, Aged, 80 and over, education.field_of_study, Progressive multifocal leukoencephalopathy, BUDGET IMPACT ANALYSIS, General Medicine, Middle Aged, Fingolimod, 3. Good health, 317 Pharmacy, Cost driver, Costs and Cost Analysis, Female, Immunosuppressive Agents, medicine.drug, Adult, medicine.medical_specialty, Cost, Travelling, Population, Drug Costs, Multiple sclerosis, 03 medical and health sciences, Multiple Sclerosis, Relapsing-Remitting, Humans, education, Adverse effect, Aged, business.industry, Fingolimod Hydrochloride, medicine.disease, 3141 Health care science, PRINCIPLES, Emergency medicine, business, 030217 neurology & neurosurgery

وصف الملف: fulltext; 800–818

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8273163b8d1bea75d4dcbe4462709a58
https://pubmed.ncbi.nlm.nih.gov/31873868